Background {#sec1}
==========

Since the H1N1 vaccine approval on October 21, 2009 in Canada, the largest vaccination program in the country's history has been rolled out. The vaccine's efficacy and the program's effectiveness [@ref-2495794129] have been estimated. However, in the face of rising vaccination program costs, there is increasing public discussion about whether the program represents good value for the healthcare dollar.

Methods  {#sec2}
========

We performed a cost-utility analysis from the health care payer perspective perspective in the Canadian province of Ontario (population 13,000,000). This economic evaluation utilized a simulation model of a pandemic (H1N1) 2009 outbreak in a Canada city [@ref-4153287573]. Attack rates for symptomatic cases were projected for four age groups under two strategies: (a) no vaccination, and (b) mass vaccination of 10% of the population per week, starting 40 days into the pandemic and lasting until 30% vaccine coverage is reached. We assume it takes 20 days for an individual to develop immunity. Patients with influenza A (H1N1) were treated with oseltamivir. Population-weighted mean predicted attack rates were 21% and 11% for strategies (a) and (b) respectively. Probabilities for health care resource use (office visits, emergency department (ED) visits, hospitalizations, intensive care unit (ICU) admissions, use of extracorporeal membrane oxygenation (ECMO)) and deaths were based on pandemic (H1N1) surveillance data in Ontario and Australia, and Ontario administrative data, covering the entire population of Canada's most populous province. Hospitalization rates for Ontario were estimated from laboratory-confirmed cases, likely representing a significant underestimate of the true burden of disease. We therefore inflated reported rates 100-fold to account for expected underrepresentation of less severe H1N1 cases among laboratory-confirmed cases. This is consistent with estimates from the United States [@ref-2161349705] and produces conservative predictions for number of hospitalizations, ICU admissions and deaths. Program and other costs were drawn from Ontario sources (Ontario Health Insurance Plan (OHIP), Ontario Case Costing Initiative (OCCI) [@ref-3266103383]). Utility weights were obtained from the literature [@ref-3717557567] and annualized. Years of life lost were calculated using average life expectancy adjusted for quality of life [@ref-2100819557].

Main outcome measures were quality adjusted life-years (QALYs), costs in 2009 Canadian dollars, and cost per QALY gained.

**Table 1:** Predicted pandemic (H1N1) 2009 attack rates in Ontario [@ref-4153287573]

**Age GroupNo InterventionImmunization program covering 30% of the population starting 40 days into the pandemic**0-4 years0.250.125-19 years0.390.2220-64 years0.170.0865+ years0.150.07Weighted mean0.210.11

**Table 2:** Pandemic (H1N1) 2009 Related Events

**EventValueSource**Office Visits^(a)^ 50% of visits for seasonal influenza \[OHIP\]   0-4 years0.39    5-19 years0.39    20-64 years0.39    65+ years0.39 ED Visits^(b)^     0-4 years0.1050% of visits for seasonal influenza \[OHIP\]\
    5-19 years0.10    20-64 years0.10    65+ years0.10 Hospitalization Ontario H1N1 Spring Wave, denominator adjusted by 1/100 (100 symptomatic case per laboratory-confirmed case) [@ref-2421790903]   0-4 years0.00221    5-19 years0.00044    20-64 years0.00083    65+ years0.00325 ICU Admission (non-ECMO) if hospitalized^(c)^ Australia H1N1 Data [@ref-357106935]   0-4 years0.03    5-19 years0.05    20-64 years0.18    65+ years0.16 ECMO if in ICU Kumar A et al 2009 [@ref-1826963633]   0-4 years0.042    5-19 years0.042    20-64 years0.042    65+ years0.042 Death per Hospitalized Case^(d)^ Australia H1N1 Data [@ref-357106935]   0-4 years0.00532    5-19 years0.01144    20-64 years0.04424    65+ years0.09059 

Note: (a) 1.12 office visits per person (b) 1.17 Emergency Department visits per person (c) overall probability for ICU admission in Australia 0.13, in Ontario for the period August 30 to November 7, 2009: 0.12 (no age-specific rates available); (d) overall probability of death if hospitalized in Australia: 0.038, in Ontario for the period August 30 to November 7, 2009: 0.036 (no age-specific rates available); ED = emergency department; ICU = intensive care unit; ECMO = extracorporeal membrane oxygenation; OHIP = Ontario Health Insurance Plan; OCCI = Ontario Case Costing Initiative

**Table 3:** Pandemic (H1N1) 2009 Economic Data

**EventValueSource**Quality of life (annualized)     No Influenza1.0Assumption   Symptomatic influenza Turner D 2003 [@ref-3717557567]      0-4 years0.9854       5-19 years0.9854       20-64 years0.9826       65+ years0.9707    Death0.5AssumptionLife years lost (undiscounted) Statistics Canada 2008 [@ref-1056611831], Mittmann N 1999 [@ref-2100819557]   0-4 years71.60    5-19 years62.26    20-64 years34.44    65+ years5.07 Unit Cost (C\$)     Immunization per dose30Waldie P, 2009 [@ref-3080267027]   Office visit35OHIP (seasonal influenza)   ED visit220OHIP (seasonal influenza)\
JPPC for non-physician costs (A9)   Hospitalization (non-ICU) OCCI data 2007/2008 [@ref-3266103383]      0-4 years4,265       5-19 years4,265       20-64 years4,016       65+ years4,016    ICU (non-ECMO) OCCI data 2007/2008 [@ref-3266103383]      0-4 years14,350       5-19 years14,350       20-64 years11,676       65+ years11,676    ICU+ECMO142,132OCCI data 2007/2008 [@ref-3266103383]

ED = emergency department; ICU = intensive care unit; ECMO = extracorporeal membrane oxygenation; OHIP = Ontario Health Insurance Plan; OCCI = Ontario Case Costing Initiative

Results {#sec3}
=======

Ontario's H1N1 immunization program is estimated to cost \$118 million (\$30 per person vaccinated). Immunizing 30% of the population prevents approximately 1.4 million cases, 850 hospitalizations and 35 deaths. This reduces healthcare cost due to illness from \$154 million to \$77 million and is associated with 24,864 additional quality-adjusted life-years for the population. The incremental cost-effectiveness ratio (ICER) is \$1,645 per QALY gained. Results are sensitive to immunization program effectiveness and cost. If the program reduces the number of cases by only 25%, the ICER increases to \$6,333 per QALY gained. Finally, if immunization costs are \$50 per person vaccinated, the ICER compared to no intervention increases to \$4,798 per QALY gained for 30% vaccination coverage. In all sensitivity analyses the ICER remains well below established thresholds, which determine the cost-effectiveness of a program [@ref-3843154625].

**Table 4:**Aggregated Results for Base Case Analysis

** No Intervention**\
**Expected30% Coverage**\
**Expected30% Coverage**\
**Incremental**Number Immunized03,920,7553,920,755Cases2,785,2591,399,598-1,385,661Deaths6732-35Resource Use (Frequency)   Office visits1,201,004603,507-597,497   ED Visits309,582155,565-154,016   Hospitalizations (All)1,670817-853   Ward1,449711-738   ICU212101-110   ICU+ECMO94-5Cost (C\$)   Immunization0117,622,638117,622,638   Office visits68,843,25234,593,856-34,249,395   ED Visits74,722,93437,548,407-37,174,527   Hospitalizations (All)10,333,0225,025,517-5,307,506      Ward6,485,5023,180,954-3,304,548      ICU2,528,4281,213,146-1,315,282      ICU+ECMO1,319,093631,416-687,676Total Health Care153,899,20777,167,780-76,731,427Total Cost153,899,207194,790,41840,891,211QALYs124,932,891124,957,75624,864

ED = emergency department; ICU = intensive care unit; ECMO = extracorporeal membrane oxygenation; QALY = quality-adjusted life year

**Table 5:** Aggregated Results for Sensitivity Analyses

 **No Intervention**\
**Expected30% Coverage**\
**Expected30% Coverage**\
**Incremental***Base Case*Cases2,785,2591,399,598-1,385,661Hospitalizations1,670817-853Deaths6732-35Total Cost153,899,207194,790,41840,891,211QALYs (undiscounted)124,932,891124,957,75624,864ICER (Cost/QALY)  1,645*Sensitivity Analysis: Ratio 1/60*Cases2,785,2591,399,598-1,385,661Hospitalizations2,7831,362-1,421Deaths11153-58Total Cost160,787,889198,140,76237,352,874QALYs (undiscounted)124,932,053124,957,34925,296ICER (Cost/QALY)  1,477*Sensitivity Analysis: Ratio 1/200*Cases2,785,2591,399,598-1,385,661Hospitalizations835409-426Deaths3316-17Total Cost148,732,696192,277,66043,544,964QALYs (undiscounted)124,933,520124,958,06124,541ICER (Cost/QALY)  1,774*Sensitivity Analysis: lower vaccine program effectiveness*Cases2,785,2592,099,397-685,863Hospitalizations1,6701,226-444Deaths6748-19Total Cost153,899,207233,374,30879,475,101QALYs (undiscounted)124,932,891124,945,44012,549ICER (Cost/QALY)  6,333*Sensitivity Analysis: high vaccination cost (\$50 per person)*Cases2,785,2591,399,598-1,385,661Hospitalizations1,670817-853Deaths6732-35Total Cost153,899,207273,205,510119,306,303QALYs (undiscounted)124,932,891124,957,75624,864ICER (Cost/QALY)  4,798

ICER = Incremental cost-effectiveness ratio

Discussion {#sec4}
==========

We estimate that the pandemic (H1N1) 2009 mass immunization program in Ontario, Canada is highly cost-effective under conservative assumptions on healthcare resource use, costs, and mortality. This is consistent with the economic attractiveness demonstrated for seasonal influenza programs [@ref-4181632009] [@ref-2139360347].

Estimates of hospitalizations and mortality are based on laboratory-confirmed cases. In the base case, we expect 67 deaths. By contrast, the average annual estimated number of deaths related to seasonal influenza in Ontario is 500 to 1,200 ([@ref-3058150761], and J.C. Kwong, unpublished). While the number of deaths associated with the 2009 pandemic may be lower in part because of relative sparing of older adults from disease, counting only laboratory-confirmed cases may also cause a significant underestimation. Similarly, we only include costs directly related to the treatment of pandemic (H1N1) cases. For example, the effects of the increased demand on health care services\--such as cancelling elective surgery\--are not included. Also, because of limited data this analysis also does not include vaccine-associated adverse events. While inclusion of serious adverse events reduces cost-effectiveness, we would not expect it to diminish the fundamental cost-effectiveness of the program if the incidence of such events remains low [@ref-4153287573].

Public health physicians and officials have traditionally focused on containing the spread of infectious disease and mitigating disease burden. But those who organize and deliver public health services are also faced with the resource constraints that affect every other part of the healthcare system. We think it is unlikely that economic considerations will ever be, or should ever be uppermost in the minds of those battling a pandemic. However, it is reassuring to know that Canada\'s response to the current pandemic appears to be reasonable when viewed through the lens of careful stewardship of scarce resources. 
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